Director/PDMR Shareholding

RNS Number : 6907R

ValiRx PLC

07 July 2022

 

7 July 2022

ValiRx PLC ("ValiRx" or the "Company")

Directors' Dealing

ValiRX, a life science company focusing on early-stage cancer therapeutics and women's health, announced 30 June 2022 that certain directors confirmed their intention to participate in the Placing  that was announced on that date.  

The table below sets out details of their participation in the Placing at a price of 10 pence per share.

Director	Ordinary Shares Purchased	Resultant Shareholding	% of Issued Share Capital
Suzanne Dilly	100,000	416,668	0.46%
Martin Lampshire	100,000	144,000	0.16%
Kevin Cox	100,000	372,333	0.41%
Gerry Desler	25,000	128,668	0.14%

*** ENDS ***

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	Tel: [phone] www.valirx.com [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: [phone]
Cenkos Securities Limited (Joint Broker) Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	Tel: [phone]
Turner Pope Investments (TPI) Limited  (Joint Broker) James Pope / Andy Thacker	Tel: [phone]

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.   https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	a)  Suzanne Dilly b) Martin Lampshire c)  Kevin Cox d)  Gerry Desler
2	Reason for notification
a.	Position/Status	a) Director b) Director c) Director d) Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	ValiRx PLC
b.	LEI	213800VQKB9SJCQDET40
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares  ISIN: GB00BLH13C52
b.	Nature of the transaction	Purchase of shares as part of the Placing
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			a) 10p b) 10p c) 10p d) 10p	a) 100,000 b) 100,000 c) 100,000 d) 25,000
d.	Aggregated information - Aggregated Volume - Price	N/A
e.	Date of the transaction	a) 07/07/2022 b) 07/07/2022 c) 07/07/2022 d) 07/07/2022
f.	Place of the transaction	London, UK

 

END

 

 

DSHBGGDRUGGDGDR